[go: up one dir, main page]

DE69525544D1 - Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose - Google Patents

Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Info

Publication number
DE69525544D1
DE69525544D1 DE69525544T DE69525544T DE69525544D1 DE 69525544 D1 DE69525544 D1 DE 69525544D1 DE 69525544 T DE69525544 T DE 69525544T DE 69525544 T DE69525544 T DE 69525544T DE 69525544 D1 DE69525544 D1 DE 69525544D1
Authority
DE
Germany
Prior art keywords
multiple sclerosis
human
protein
myeline
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69525544T
Other languages
English (en)
Other versions
DE69525544T2 (de
Inventor
Nicholas Ling
J Conlon
Amitabh Gaur
Lawrence Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of DE69525544D1 publication Critical patent/DE69525544D1/de
Publication of DE69525544T2 publication Critical patent/DE69525544T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69525544T 1994-11-18 1995-11-16 Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose Expired - Fee Related DE69525544T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34207894A 1994-11-18 1994-11-18
PCT/US1995/014402 WO1996016085A1 (en) 1994-11-18 1995-11-16 Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Publications (2)

Publication Number Publication Date
DE69525544D1 true DE69525544D1 (de) 2002-03-28
DE69525544T2 DE69525544T2 (de) 2002-08-22

Family

ID=23340234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525544T Expired - Fee Related DE69525544T2 (de) 1994-11-18 1995-11-16 Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose

Country Status (9)

Country Link
US (4) US6369033B1 (de)
EP (2) EP0792286B1 (de)
JP (1) JPH10509714A (de)
AT (1) ATE213499T1 (de)
AU (1) AU721898B2 (de)
CA (1) CA2205532A1 (de)
DE (1) DE69525544T2 (de)
MX (1) MX9703642A (de)
WO (1) WO1996016085A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
EP0650498B1 (de) * 1992-04-09 1998-09-09 Autoimmune, Inc. Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
WO1997030150A2 (en) * 1996-02-15 1997-08-21 Pangenetics B.V. Molecules for the induction of immunological tolerance
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6541608B1 (en) * 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
WO2002077025A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
PL214283B1 (pl) * 2002-08-08 2013-07-31 Baylor College Medicine Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T
KR20070122563A (ko) 2005-04-19 2007-12-31 일라이 릴리 앤드 캄파니 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
WO2007131210A2 (en) * 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
CN103102393B (zh) * 2013-01-30 2015-01-07 北京大学 一种多肽及其在制备抑郁症治疗药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
JPH05508621A (ja) * 1990-03-02 1993-12-02 オートイミューン　インク 自己抗原の経口投与による自己免疫疾患のダウンコントロール
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
DE69230612T2 (de) * 1991-05-31 2000-06-21 Connetics Corp., Palo Alto T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
EP0650498B1 (de) * 1992-04-09 1998-09-09 Autoimmune, Inc. Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
US20020058627A1 (en) 2002-05-16
DE69525544T2 (de) 2002-08-22
US6489299B2 (en) 2002-12-03
CA2205532A1 (en) 1996-05-30
WO1996016085A1 (en) 1996-05-30
US20040214775A1 (en) 2004-10-28
EP1172376A1 (de) 2002-01-16
EP0792286B1 (de) 2002-02-20
JPH10509714A (ja) 1998-09-22
US20030114380A1 (en) 2003-06-19
US6369033B1 (en) 2002-04-09
ATE213499T1 (de) 2002-03-15
AU4405796A (en) 1996-06-17
AU721898B2 (en) 2000-07-20
EP0792286A1 (de) 1997-09-03
US6740638B2 (en) 2004-05-25
MX9703642A (es) 1998-11-29

Similar Documents

Publication Publication Date Title
DE69525544D1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
DE3852636D1 (de) Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
ATE230797T1 (de) Stabile produkte des bakterientötenden/durchlässigkeiterhöhenden proteins (pbi) und diese enthaltende arzneimittelzusammensetzungen
HUT49891A (en) Process for production of peptides with antiaggregation effect and medical compositions containing them
OA06421A (fr) Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
ATE377026T1 (de) Behandlung von fettleibigkeit
ATE60062T1 (de) Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren.
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
DE69430416D1 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
ATE92078T1 (de) Pharmakologisch aktive peptide.
DK34590D0 (da) Biologisk aktive molekyler
KR890700673A (ko) 돼지 성장호르몬 아날로그
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
DE3882233D1 (de) Gefaessaktive peptide.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee